Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 355 participants.

Also called NCT02644941

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 355 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02644941
  • EudraCT 2015-003261-28
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Germany, Israel, Poland, Portugal, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02644941. Randomized; no masking; primary purpose treatment. Start 2016-05-24 (actual); primary completion 2019-05 (actual). Results posted on 2025-03-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis
Condition
Renal Failure
Condition
End Stage Renal Disease
Condition
Hemodialysis
Condition
Vascular Access
Intervention (Biological)
Human Acellular Vessel (HAV)
Intervention (Device)
ePTFE graft
Lead sponsor
Humacyte, Inc. (class: industry)
Collaborator
CTI Clinical Trial and Consulting Services (class: other)
Collaborator
California Institute for Regenerative Medicine (CIRM) (class: other)

Record details

Record id
cardio:ct-nct02644941
Content hash
ac56f1859191cdd2519ad625c38dd12646751085d706d2e9ce100b5b9341b3f0